Eurofins strengthens its position in the UK Forensics market
May 21, 2008
London May 21, 2008
Eurofins has strengthened its position in the UK Forensic market with the acquisition of the assets of Defence Forensics Ltd, a DNA forensic laboratory, based in Newport Wales. The purpose built laboratory specialises in DNA crime scene stains analysis and complements Eurofins’ growing network of forensic DNA and Toxicology laboratories across Europe. The new laboratory will trade as Eurofins Forensic Services. Commenting on the acquisition, John Rowley, Managing Director of Eurofins Forensic and Applied Genetics division said, “The acquisition is an important step in Eurofins' strategic development and continuing investment in the forensic market in the United Kingdom. Building on our existing activities in Continental Europe, we look forward to providing the UK Police Forces and Criminal Justice customers with enhanced services from our new facility.”
For more information about Eurofins, please visit www.eurofins.com , http://www.eurofinsforensics.co.uk/ or contact:
Paul Hackett, Eurofins Genetic Services, 318 Worple Road, Raynes Park, London SW20 8QU, United Kingdom, Tel: +44 (0) 7713 053601
Investor Relations, Tel.: +32-2-769 7383, E-mail: ir@eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With about 7,000 staff in more than 150 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.
